NO20052096L - Fremgangsmater for a danne og screene for proteaser med endret spesifisitet. - Google Patents

Fremgangsmater for a danne og screene for proteaser med endret spesifisitet.

Info

Publication number
NO20052096L
NO20052096L NO20052096A NO20052096A NO20052096L NO 20052096 L NO20052096 L NO 20052096L NO 20052096 A NO20052096 A NO 20052096A NO 20052096 A NO20052096 A NO 20052096A NO 20052096 L NO20052096 L NO 20052096L
Authority
NO
Norway
Prior art keywords
methods
screening
forming
altered specificity
proteases
Prior art date
Application number
NO20052096A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052096D0 (no
Inventor
Jack Nguyen
Chris Thanos
Sandra Waugh Ruggles
Charles S Craik
Original Assignee
Catalyst Biosciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalyst Biosciences filed Critical Catalyst Biosciences
Publication of NO20052096D0 publication Critical patent/NO20052096D0/no
Publication of NO20052096L publication Critical patent/NO20052096L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
NO20052096A 2002-10-02 2005-04-29 Fremgangsmater for a danne og screene for proteaser med endret spesifisitet. NO20052096L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41538802P 2002-10-02 2002-10-02
PCT/US2003/031719 WO2004031733A2 (en) 2002-10-02 2003-10-02 Methods of generating and screenign for porteases with altered specificity

Publications (2)

Publication Number Publication Date
NO20052096D0 NO20052096D0 (no) 2005-04-29
NO20052096L true NO20052096L (no) 2005-06-28

Family

ID=32069849

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052096A NO20052096L (no) 2002-10-02 2005-04-29 Fremgangsmater for a danne og screene for proteaser med endret spesifisitet.

Country Status (13)

Country Link
US (2) US20040146938A1 (xx)
EP (3) EP2444810A3 (xx)
JP (3) JP5376747B2 (xx)
KR (3) KR101132555B1 (xx)
CN (2) CN104630192A (xx)
AU (2) AU2003282724B2 (xx)
CA (1) CA2501295A1 (xx)
MX (1) MXPA05003493A (xx)
NO (1) NO20052096L (xx)
NZ (2) NZ590187A (xx)
SG (2) SG188669A1 (xx)
WO (1) WO2004031733A2 (xx)
ZA (1) ZA200502867B (xx)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101132555B1 (ko) * 2002-10-02 2012-04-02 리전츠 오브 더 유니버시티 오브 캘리포니아 변경된 특이성을 갖는 프로테아제의 제조 및 선별 방법
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
CA2534629C (en) * 2003-08-06 2016-01-19 University Of Maryland Biotechnology Institute Engineered proteases for affinity purification and processing of fusion proteins
AU2005244271B2 (en) * 2004-04-12 2010-04-08 Vertex Pharmaceuticals Incorporated Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1
WO2005100556A2 (en) * 2004-04-12 2005-10-27 Catalyst Biosciences Cleavage of vegf and vegf receptor by wild-type and mutant proteases
JP2006117594A (ja) * 2004-10-22 2006-05-11 Shiseido Co Ltd 活性型カスパーゼ−１４特異的抗体及びその作成方法
KR101314899B1 (ko) 2005-03-22 2013-10-04 로도세이야구가부시기가이샤 콜라겐 또는 히알루론산 생성을 증가시키는 펩티드
US20070093443A1 (en) * 2005-10-21 2007-04-26 Madison Edwin L Modified proteases that inhibit complement activation
EP2423307A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IV polypeptides and use thereof for treatment
KR20170014023A (ko) * 2006-07-05 2017-02-07 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
KR20100016462A (ko) 2007-04-13 2010-02-12 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도
TWI538916B (zh) 2008-04-11 2016-06-21 介控生化科技公司 經修飾的因子vii多肽和其用途
PL4032979T3 (pl) 2008-09-15 2024-09-30 Uniqure Biopharma B.V. Mutant polipeptydu czynnika ix, jego zastosowania i sposób jego otrzymywania
US10577639B2 (en) 2009-06-26 2020-03-03 University Of Florida Research Foundation, Inc. Rapid bed-side measurement of neutrophil elastase activity in biological fluids
US20120270241A1 (en) * 2009-09-23 2012-10-25 Bryan Philip N Systems and methods for evolving enzymes with desired activities
WO2012038049A2 (en) * 2010-09-22 2012-03-29 Roche Diagnostics Gmbh Amplification of distant nucleic acid targets using engineered primers
TWI557135B (zh) 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途
JP5851092B2 (ja) * 2010-12-24 2016-02-03 株式会社明治 ペプチド組成物、およびその製造方法
EP2658971A1 (en) 2010-12-28 2013-11-06 XOMA Technology Ltd. Cell surface display using pdz domains
WO2013041659A2 (en) * 2011-09-23 2013-03-28 Pharmedartis Gmbh Novel serine protease variants
CA3100606C (en) * 2012-05-25 2023-08-01 Chr. Hansen A/S Variants of chymosin with improved milk-clotting properties
CN104755492A (zh) 2012-07-25 2015-07-01 催化剂生物科学公司 修饰的因子x多肽及其应用
WO2014055836A2 (en) * 2012-10-04 2014-04-10 Research Development Foundation Serine protease molecules and therapies
UA121380C2 (uk) 2014-02-26 2020-05-25 Кр. Гансен А/С Поліпептид хімозину з удосконаленими властивостями щодо згортання молока
CA2947198C (en) * 2014-04-29 2023-01-17 Novartis Ag Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
AU2015371265B2 (en) 2014-12-24 2021-06-03 Neximmune, Inc Nanoparticle compositions and methods for immunotherapy
EP4079849A1 (en) 2015-06-22 2022-10-26 Chr. Hansen A/S Variants of chymosin with improved properties
BR112018003493A2 (pt) 2015-08-31 2018-09-18 Chr Hansen As variantes de quimosina com propriedades aperfeiçoadas
US11702477B2 (en) 2015-11-06 2023-07-18 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
EP3377080B1 (en) 2015-11-19 2024-02-14 Asclepix Therapeutics, LLC Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
CN109071627B (zh) 2016-02-05 2023-04-04 奥里尼斯生物科学私人有限公司 Cd8结合剂
WO2017153402A1 (en) 2016-03-07 2017-09-14 Vib Vzw Cd20 binding single domain antibodies
CA3023881A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
CA3023883A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
US12019066B2 (en) * 2016-05-16 2024-06-25 Biomadison, Inc. Assay with synaptobrevin based moiety
CN109640677A (zh) 2016-05-19 2019-04-16 科·汉森有限公司 具有改善的凝乳特性的凝乳酶的变体
AR108527A1 (es) 2016-05-19 2018-08-29 Chr Hansen As Variantes de quimosina con propiedades mejoradas de coagulación de leche
SG10202103032QA (en) 2016-10-04 2021-05-28 Asclepix Therapeutics Inc Compounds and methods for activating tie2 signaling
BR102017010169A2 (pt) * 2017-05-15 2019-02-26 Remer Consultores Assessoria Empresarial Ltda. composto, intermediário de síntese, uso na preparação de anticonvulsivante, composição farmacêutica anticonvulsivante
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
GB201622422D0 (en) * 2016-12-30 2017-02-15 Dublin Inst Of Tech Peptide prediction
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
IL268346B2 (en) 2017-02-06 2024-08-01 Orionis Biosciences BV Targeted chimeric proteins and their uses
US11246911B2 (en) 2017-02-07 2022-02-15 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
EP3641801A1 (en) 2017-06-22 2020-04-29 Catalyst Biosciences, Inc. Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
US12059476B2 (en) 2017-10-10 2024-08-13 The Johns Hopkins University Biodegradable biomimetic particles
CN108241054B (zh) * 2017-12-26 2021-03-12 天津市中西医结合医院（天津市南开医院） 检测g蛋白偶联受体18的试剂在制备败血症诊断及病程监测和预后判断试剂中表达的应用
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
US11896643B2 (en) 2018-02-05 2024-02-13 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
JP2022516725A (ja) 2018-12-28 2022-03-02 カタリスト・バイオサイエンシーズ・インコーポレイテッド 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法
JP2022520632A (ja) 2019-02-15 2022-03-31 インテグラル・モレキュラー・インコーポレイテッド 共通軽鎖を含む抗体及びその使用
BR112021016056A2 (pt) 2019-02-15 2021-12-14 Integral Molecular Inc Anticorpos de claudina 6 e usos dos mesmos
WO2020210455A1 (en) * 2019-04-09 2020-10-15 University Of Houston System Engineered chymotrypsins and uses thereof
CN110079514A (zh) * 2019-04-12 2019-08-02 江苏大学 一种制备蛋白酶3重组蛋白的方法
EP3833381B1 (en) 2019-08-15 2022-08-03 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
CN112322722B (zh) * 2020-11-13 2021-11-12 上海宝藤生物医药科技股份有限公司 检测16p11.2微缺失的引物探针组合物、试剂盒及其应用
WO2024008755A1 (en) 2022-07-04 2024-01-11 Vib Vzw Blood-cerebrospinal fluid barrier crossing antibodies
WO2024118771A1 (en) 2022-11-30 2024-06-06 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
WO2024208816A1 (en) 2023-04-03 2024-10-10 Vib Vzw Blood-brain barrier crossing antibodies

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5801038A (en) * 1984-05-29 1998-09-01 Genencor International Inc. Modified subtilisins having amino acid alterations
US5185258A (en) * 1984-05-29 1993-02-09 Genencor International, Inc. Subtilisin mutants
DK6488D0 (da) * 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5304482A (en) * 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US6271012B1 (en) * 1989-10-11 2001-08-07 Genencor International, Inc. Protease muteins and their use in detergents
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
US6335160B1 (en) * 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5766842A (en) * 1994-09-16 1998-06-16 Sepracor, Inc. In vitro method for predicting the evolutionary response of a protein to a drug targeted thereagainst
US6165794A (en) * 1994-11-10 2000-12-26 The Regents Of The University Of California Suppression of proteolytic activity by dysfunctional protease formation
GB9618960D0 (en) * 1996-09-11 1996-10-23 Medical Science Sys Inc Proteases
US7083786B2 (en) * 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
DE19743683A1 (de) * 1997-10-02 1999-04-08 Basf Ag Verfahren zur Änderung der Substratspezifität von Enzymen
US20030186329A1 (en) * 1999-03-22 2003-10-02 The Scripps Research Institute Use of substrate subtraction libraries to distinguish enzyme specificities
US20020068320A1 (en) * 2000-03-14 2002-06-06 Yanggu Shi Serine protease polynucleotides, polypeptides, and antibodies
DE19943177C2 (de) * 1999-09-09 2002-10-24 Dieter Jenne Verfahren zur Herstellung von aktiven Serienproteasen und inaktiven Varianten
US7030231B1 (en) * 1999-09-30 2006-04-18 Catalyst Biosciences, Inc. Membrane type serine protease 1 (MT-SP1) and uses thereof
US20030171252A9 (en) * 2000-01-31 2003-09-11 Rosen Craig A. Nucleic acids, proteins, and antibodies
CA2400187A1 (en) * 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
US20020031801A1 (en) * 2000-03-24 2002-03-14 Millennium Pharmaceuticals, Inc. 18806, a novel trypsin serine protease-like molecule and uses thereof
WO2001094332A1 (en) * 2000-06-02 2001-12-13 Regents Of The University Of California Profiling of protease specificity using combinatorial fluorogenic substrate libraries
US7157596B2 (en) * 2000-09-08 2007-01-02 Dendreon Corporation Inhibitors of serine protease activity of matriptase or MTSP1
US6797461B2 (en) * 2000-10-27 2004-09-28 Promega Corporation Tryptase substrates and assay for tryptase activity using same
US20030104591A1 (en) * 2000-12-14 2003-06-05 Murray Christopher J. Methods and compositions for grafting functional loops into a protein
US20030049689A1 (en) * 2000-12-14 2003-03-13 Cynthia Edwards Multifunctional polypeptides
US20030068792A1 (en) * 2000-12-14 2003-04-10 Yiyou Chen Targeted enzymes
WO2003089648A1 (en) * 2002-04-22 2003-10-30 Novozymes Biotech, Inc. Methods for preparing variants of a dna sequence in filamentous fungi
US20040072276A1 (en) * 2002-05-10 2004-04-15 Direvo BioTech AG. Process for generating sequence-specific proteases by directed evolution and use thereof
AU2003262937B2 (en) * 2002-08-27 2009-05-07 Bristol-Myers Squibb Company Adzymes and uses thereof
ES2343518T3 (es) * 2002-09-09 2010-08-03 Hanall Biopharma Co., Ltd. Polipeptidos interferon alfa modificados resistentes a proteasas.
US7939304B2 (en) * 2002-10-02 2011-05-10 Catalyst Biosciences, Inc. Mutant MT-SP1 proteases with altered substrate specificity or activity
US20060024289A1 (en) * 2002-10-02 2006-02-02 Ruggles Sandra W Cleavage of VEGF and VEGF receptor by wild-type and mutant proteases
KR101132555B1 (ko) * 2002-10-02 2012-04-02 리전츠 오브 더 유니버시티 오브 캘리포니아 변경된 특이성을 갖는 프로테아제의 제조 및 선별 방법
US20040115727A1 (en) * 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US7335504B2 (en) * 2003-06-18 2008-02-26 Direvo Biotechnology Ag Engineered enzymes and uses thereof
CA2529589A1 (en) * 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the pharmaceutical or diagnostic use thereof
US7439226B2 (en) * 2003-09-30 2008-10-21 The United States Of America As Represented By The Department Of Health And Human Services Serine protease inhibitors
AU2005244271B2 (en) * 2004-04-12 2010-04-08 Vertex Pharmaceuticals Incorporated Cleavage of VEGF and VEGF receptor by wildtype and mutant MT-SP1
EP1726643A1 (en) * 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
US7974395B2 (en) * 2005-09-28 2011-07-05 Avaya Inc. Detection of telephone number spoofing
US20070093443A1 (en) * 2005-10-21 2007-04-26 Madison Edwin L Modified proteases that inhibit complement activation
EP1976861A2 (en) * 2005-11-29 2008-10-08 The Scripps Research Institute Inhibiting tumour cell invasion, metastasis and angiogenesis through targetting legumain
KR20170014023A (ko) * 2006-07-05 2017-02-07 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
KR20100016462A (ko) * 2007-04-13 2010-02-12 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 제ｖｉｉ 인자 폴리펩타이드 및 이의 용도
TWI557135B (zh) * 2010-11-03 2016-11-11 介控生化科技公司 經修飾之第九因子多胜肽及其用途

Also Published As

Publication number Publication date
CA2501295A1 (en) 2004-04-15
KR101132555B1 (ko) 2012-04-02
MXPA05003493A (es) 2005-09-30
EP2444809A3 (en) 2013-07-24
AU2003282724B2 (en) 2010-03-04
JP5376747B2 (ja) 2013-12-25
EP2444810A3 (en) 2013-01-02
EP2444809A2 (en) 2012-04-25
WO2004031733A3 (en) 2007-03-15
KR20100109969A (ko) 2010-10-11
JP2012254988A (ja) 2012-12-27
US20090136477A1 (en) 2009-05-28
NO20052096D0 (no) 2005-04-29
AU2003282724A1 (en) 2004-04-23
KR20120088836A (ko) 2012-08-08
EP1608947A4 (en) 2009-06-17
KR20050083717A (ko) 2005-08-26
AU2010201204B2 (en) 2012-09-20
NZ539242A (en) 2009-07-31
EP2444810A2 (en) 2012-04-25
ZA200502867B (en) 2007-09-26
WO2004031733A2 (en) 2004-04-15
AU2010201204A1 (en) 2010-04-15
EP1608947A2 (en) 2005-12-28
JP2006518983A (ja) 2006-08-24
JP2010099082A (ja) 2010-05-06
SG166001A1 (en) 2010-11-29
NZ590187A (en) 2012-07-27
CN101124484A (zh) 2008-02-13
SG188669A1 (en) 2013-04-30
US20040146938A1 (en) 2004-07-29
CN104630192A (zh) 2015-05-20

Similar Documents

Publication Publication Date Title
NO20052096L (no) Fremgangsmater for a danne og screene for proteaser med endret spesifisitet.
ATE504315T1 (de) Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen
DK1680507T3 (da) Bakterieekspression af proteaseinhibitorer og varianter deraf
ATE520411T1 (de) Behandlung und prävention von lungenerkrankungen
CY1114916T1 (el) Μεθοδοι
WO2005100556A3 (en) Cleavage of vegf and vegf receptor by wild-type and mutant proteases
MX342777B (es) Inhibidores tnfa para usarse en el tratamiento de trastornos relacionados con tnfa.
EA200700538A1 (ru) Соединения пиридиловых ингибиторов передачи сигналов белком hedgehog, способ их получения, композиция и способы лечения рака и ингибирований ангиогенеза и сигнального пути hedgehog в клетках на их основе
DE60230029D1 (de) Immunisierungstherapie zur behandlung von atherosklerose
DE60226051D1 (de) Pyrazolidinon-verbindungen als liganden des ep2 und/oder ep4 prostaglandin-rezeptoren
WO2006067198A3 (en) Targeted use of engineered enzymes
DK1694354T3 (da) Fremgangsmåde til at forhindre og behandle diabetes ved anvendelse af neurturin
EP1638505A4 (en) AMPHIPHILI PYRIDINIUM COMPOUNDS, METHOD OF MANUFACTURE AND ITS USE
NO20051169L (no) Fremgangsmate for a isolere et intestinalt kolesterolbindende protein
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
SG158739A1 (en) Aggrecanase molecules
DE69825733D1 (de) Spezifische inhibitoren der pankreatischen lipase und deren anwendungen
DE60329326D1 (de) Tace inhibitoren
NO20075461L (no) Neurotrypsin inhibitorer
PL336298A1 (en) Method of obtaining 2-aryl-3-aryl-halopyridines useful as cox-2 inhibitors
NO20042053L (no) Kloestillende middel
HUP0102243A2 (hu) sPLA2-inhibitor vegyületek betegség kezelésére
DE60334316D1 (de) Frpb proteinmutante und verfahren zur erneuten faltung
WO2002100333A3 (en) Inhibitors of reggamma
EA202191582A1 (ru) Расщепляемые матриксной металлопротеазой и расщепляемые сериновой или цистеиновой протеазами субстраты и способы их применения

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application